Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

238.00USD
4:01pm EDT
Change (% chg)

$-1.36 (-0.57%)
Prev Close
$239.36
Open
$239.36
Day's High
$240.49
Day's Low
$235.78
Volume
249,815
Avg. Vol
294,067
52-wk High
$246.00
52-wk Low
$106.03

VRX.N

Chart for VRX.N

About

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $81,690.65
Shares Outstanding(Mil.): 340.86
Dividend: --
Yield (%): --

Financials

  VRX.N Industry Sector
P/E (TTM): 81.00 36.48 38.67
EPS (TTM): 2.96 -- --
ROI: 3.32 16.42 15.73
ROE: 17.50 17.24 16.79
Search Stocks

CORRECTED-UPDATE 1-FDA asks dermal filler makers to indicate risk of serious injury

May 28 - The U.S. Food and Drug Administration has asked manufacturers of dermal fillers to update their labeling to reflect the possible risk of serious injuries caused by unintentional injection of the fillers into the blood vessels in the face.

28 May 2015

FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

UPDATE 1-FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON, May 27 - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

FDA approves Actavis, Valeant drugs for irritable bowel syndrome

WASHINGTON, May 27 - U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc and Valeant Pharmaceuticals International Inc on Wednesday, validating big investments both companies made to acquire the products.

27 May 2015

Valeant in talks to buy Egyptian drugmaker Amoun Pharma: Bloomberg

- Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter.

20 May 2015

Valeant in talks to buy Egyptian drugmaker Amoun Pharma-Bloomberg

May 20 - Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter.

20 May 2015

Valeant CEO expects sharp rise in Asia revenue by 2020

MONTREAL - Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday.

19 May 2015

Valeant CEO expects sharp rise in Asia revenue by 2020

MONTREAL, May 19 - Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday.

19 May 2015

Endo pushes further into generics with $8 billion Par Pharma buy

- Endo International Plc said it would buy Par Pharmaceutical Holdings Inc from private-equity firm TPG Capital for about $8 billion, including debt, to become a top-five generic drugmaker by sales in the United States. | Video

18 May 2015

BRIEF-Medica Nord signs distribution agreement with Bausch & Lomb Nordic AB

* Enters into cooperation with Bausch & Lomb Nordic AB, a subsidiary of Valeant Pharmaceuticals Inc

11 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$49.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks